{"id":"loteprednol-etabonate-0-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Transient blurred vision"},{"rate":null,"effect":"Increased intraocular pressure"},{"rate":null,"effect":"Posterior subcapsular cataract formation (with prolonged use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a topical corticosteroid, loteprednol etabonate reduces inflammation, edema, and immune cell infiltration in ocular tissues. It is an ester-based corticosteroid designed to be metabolized more rapidly than other topical steroids, potentially reducing systemic absorption and adverse effects while maintaining local anti-inflammatory efficacy.","oneSentence":"Loteprednol etabonate is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:14.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammation and pain following ocular surgery"},{"name":"Seasonal allergic conjunctivitis"},{"name":"Uveitis"},{"name":"Dry eye disease"}]},"trialDetails":[{"nctId":"NCT05322148","phase":"PHASE3","title":"Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2022-06-03","conditions":"Dry Eye","enrollment":59},{"nctId":"NCT04708821","phase":"PHASE4","title":"DEXTENZA Therapy for Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Clinical Research Center of Florida","startDate":"2021-04-30","conditions":"Bilateral Conjunctivitis (Disorder)","enrollment":31},{"nctId":"NCT00689078","phase":"PHASE4","title":"Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2008-05","conditions":"Allergic Conjunctivitis","enrollment":36},{"nctId":"NCT04075227","phase":"PHASE4","title":"Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium","status":"COMPLETED","sponsor":"Wannisa Suphachearabhan","startDate":"2015-10-16","conditions":"Recurrent Pterygium of Eye, Steroid-Induced Glaucoma","enrollment":108},{"nctId":"NCT01443442","phase":"PHASE4","title":"Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Southern California College of Optometry at Marshall B. Ketchum University","startDate":"2011-10","conditions":"Allergic Conjunctivitis","enrollment":23},{"nctId":"NCT01435460","phase":"PHASE3","title":"Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-08","conditions":"Seasonal Allergic Conjunctivitis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alrex","Alrex (Bausch & Lomb)"],"phase":"marketed","status":"active","brandName":"Loteprednol etabonate 0.2%","genericName":"Loteprednol etabonate 0.2%","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Loteprednol etabonate is a topical corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Seasonal allergic conjunctivitis, Uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}